Φορτώνει......

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rises in bone remodelling, reductions in BMD and an in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Endocr Soc
Κύριοι συγγραφείς: Khan, Aliya, Alrob, Hajar Abu, Said, Hosay, Iqbal, Salman, Hweija, Ismail, Hussain, Sharjil
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2021
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090192/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.489
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!